The article is devoted to the issue of prescribing long-term anticoagulant therapy for patients with atrial flutter. Currently, a unified approach to prescribing anticoagulants for atrial flutter and fibrillation is generally accepted. However, this approach does not have strong evidence. The article provides a comparative analysis of the risk of thromboembolic complications and left atrium thrombosis in atrial flutter and fibrillation, discusses possible mechanisms of these differences. The results of studies confirming and refuting the unified approach to anticoagulant therapy for these arrhythmias are discussed. The author’s clinical protocol for prescribing long-term anticoagulant therapy to patients with atrial flutter is presented. a comparative analysis of current clinical recommendations on this problem is carried out.

Full Text

Restricted Access

About the authors

Irina V. Zotova

Center for Individualized Prevention and Treatment of Arterial and Venous Thrombosis City Clinical Hospital № 17; Central State Medical Academy of Department of Presidential Affairs

119620, Moscow, Russian Federation; 121359, Moscow, Russian Federation
candidate of medicine science, assistant professor, department of therapy, cardiology and functional diagnostics, Central State Medical Academy of Department of Presidential Affairs, 121359, Moscow, Russian Federation; cardiologist, heard of Center for Individualized Prevention and Treatment of Arterial and Venous Thrombosis City Clinical Hospital №17 of Moscow Healthcare department, 119620, Moscow, Russian Federation


  1. Fuster V., Ryden L.E., Asinger R.W., Cannom D.S., Crijns H.J., Frye R.L. et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J. 2001; 22(20): 1852-923.
  2. January C.T., Wann L.S., Calkins H., Chen L.Y., Cigarroa J.E., Cleveland J.C. et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. J Am Coll Cardiol. 2019; 74(1): 104-32.
  3. Al-Kawaz M., Omran S.S., Parikh N.S., Elkin, M.S.V., Soliman E.Z., Kamel H.; Comparative Risks of Ischemic Stroke in Atrial Flutter versus Atrial Fibrillation/ J Stroke Cerebrovasc Dis. 2018; 27(4): 839-44.
  4. Lin Y.S., Chen T.H., Chi C.C., Lin M.S., Tung T.H., Liu C.H. et al. Different Implications of Heart Failure, Ischemic Stroke, and Mortality Between Nonvalvular Atrial Fibrillation and Atrial Flutter-a View From a National Cohort Study. J Am Heart Assoc. 2017; 6(7): e006406. doi: 10.1161/JAHA.117.006406
  5. Cresti A., Garcia-Fernandez M.A., De Sensi F., Miracapillo G., Picchi A., Scalese M. et al. Prevalence of auricular thrombosis before atrial flutter cardioversion: a 17-year transoesophageal echocardiographic study. Europace. 2016; 18(3): 450-6.
  6. Huang J.J., Reddy S., Truong T.H., Suryanarayana P., Alpert J.S. Atrial Appendage Thrombosis Risk Is Lower for Atrial Flutter Compared with Atrial Fibrillation. Am J Med. 2018; 131(4): 442. e13-442.e17
  7. Gupta D.K., Shah A.M., Giugliano R.P., Ruff C.T., Antman E.M., Grip L.T. et al. Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. Eur Heart J. 2014; 35(22): 1457-65.
  8. Sakurai K., Hirai T., Nakagawa K., Kameyama T., Nozawa T., Asanoi H. et al. Left atrial appendage function and abnormal hypercoagulability in patients with atrial flutter. Chest. 2003; 124(5): 1670-4.
  9. Omran H., Jung W., Rabahieh R., MacCarter D., Illien S., Rang B. et al. Left atrial appendage function in patients with atrial flutter. Heart. 1997; 78(3): 250-4.
  10. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5): e1-e88
  11. Lin Y.S., Chen Y.L., Chen T.H., Lin M.S., Liu C.H., Yang T.Y. et al; Comparison of Clinical Outcomes Among Patients With Atrial Fibrillation or Atrial Flutter Stratified by CHA2DS2-VASc Score. JAMA Netw Open. 2018; 1(4): e180941. doi: 10.1001/jamanetworkopen.2018.0941
  12. Chen Y.L., Lin Y.S., Wang H.T., Liu W.H., Chen H.C., Chen M.C. Clinical outcomes of solitary atrial flutter patients using anticoagulation therapy: a national cohort study. Europace. 2019; 21(2): 313-21.
  13. Lip G.Y.H., Banerjee A., Boriani G., Chiang C., Fargo R., Freedman B. et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. CHEST. 2018; 154(5): 1121-201.
  14. Katritsis D.G., Boriani G2, Cosio F.G., Hindricks G., Jaïs P., Josephson M.E. et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). Europace. 2017; 19(3): 465-511.
  15. Andrade J.G., Verma A., Mitchell L.B., Parkash R., Leblanc K., Atzema C. et al. 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2018; 34(11): 1371-92.
  16. Steffel J., Verhamme P., Potpara T.S., Albaladejo P., Antz M., Desteghe L. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330-93.
  17. Biblo L.A., Yuan Z., Quan K.J., Mackall J.A., Rimm A.A.; Risk of stroke in patients with atrial flutter. Am J Cardiol. 2001; 87(3): 346-9; A9.
  18. Ellis K., Wazni O., Marrouche N., Martin D., Gillinov M., McCarthy P. et al. Incidence of atrial fibrillation post-cavotricuspid isthmus ablation in patients with typical atrial flutter: left-atrial size as an independent predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol. 2007; 18(8): 799-802.
  19. Chen K., Bai R., Deng W., Gao C., Zhang J., Wang X. et al. HATCH score in the prediction of new-onset atrial fibrillation after catheter ablation of typical atrial flutter. Heart Rhythm. 2015; 12(7): 1483-9.
  20. Khan I.A. Transient atrial mechanical dysfunction (stunning) after cardioversion of atrial fibrillation and flutter. Am Heart J. 2002; 144(1): 11-22.
  21. Grimm R.A., Stewart W.J., Arheart K., Thomas J.D., Klein A.L. Left atrial appendage “stunning” after electrical cardioversion of atrial flutter: an attenuated response compared with atrial fibrillation as the mechanism for lower susceptibility to thromboembolic events. J Am Coll Cardiol. 1997; 29(3): 582-9.
  22. Sakurai K., Hirai T., Nakagawa K., Kameyama T., Nozawa T., Asanoi H. et al. Prolonged activation of hemostatic markers following conversion of atrial flutter to sinus rhythm. Circ J. 2004; 68(11): 1041-4.



Abstract - 88

PDF (Russian) - 0


Article Metrics

Metrics Loading ...


  • There are currently no refbacks.

Copyright (c) 2019 Eco-Vector

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies